SERPINA3 Antibody

What is SERPINA3 and why is it important in research?

SERPINA3 is a serine protease inhibitor belonging to the serpin superfamily and functions as an alpha-1-antichymotrypsin. This 47.7 kDa protein (calculated molecular weight) plays significant roles in multiple biological processes and has been implicated in several pathological conditions . Variations in the SERPINA3 sequence have been linked to Alzheimer's disease, while deficiency of this protein has been associated with liver disease . Additionally, SERPINA3 overexpression has been connected to tumor invasion and progression in certain cancers, making it a valuable research target in oncology . The protein's involvement in these diverse pathological processes makes SERPINA3 antibodies essential tools for investigating disease mechanisms and potential therapeutic approaches.

What applications are SERPINA3 antibodies validated for?

SERPINA3 antibodies have been validated for multiple research applications, with specificity varying by antibody clone and manufacturer. Common validated applications include:

When selecting an antibody for specific research purposes, it's crucial to verify that the particular clone has been validated for your intended application . Some antibodies are specifically designed as matched antibody pairs for sandwich ELISA or other paired-antibody techniques, requiring different antibodies for capture and detection roles .

What is the difference between monoclonal and polyclonal SERPINA3 antibodies?

The choice between monoclonal and polyclonal SERPINA3 antibodies depends on your specific research needs:

Monoclonal SERPINA3 antibodies are produced from a single B-cell clone, resulting in antibodies that recognize a single epitope of the SERPINA3 protein. These provide high specificity and consistency between batches, making them ideal for standardized assays . The search results show examples like the Mouse Monoclonal SERPINA3 antibody (66078-3-PBS), which has been validated for specific applications like cytometric bead arrays and indirect ELISA .

Polyclonal SERPINA3 antibodies, such as the rabbit polyclonal antibody mentioned in search result , are derived from multiple B-cell lineages and recognize multiple epitopes on the SERPINA3 protein. These antibodies often provide stronger signals due to multiple binding sites but may have higher batch-to-batch variability . They're particularly useful for applications like Western blotting and can be more robust for detecting denatured proteins.

For applications requiring high sensitivity, polyclonal antibodies may be advantageous, while applications demanding high specificity and reproducibility might benefit from monoclonal antibodies .

How can SERPINA3 antibodies be used to investigate its role in cancer progression?

SERPINA3 has been implicated in various aspects of cancer progression, particularly in breast cancer and specifically triple-negative breast cancer (TNBC). Research has shown that SERPINA3 can regulate migration, invasion, and epithelial-mesenchymal transition (EMT) in TNBC cells, and its increased expression confers resistance to cisplatin . To investigate these processes, researchers can employ several antibody-based approaches:

For examining expression levels in clinical samples, immunohistochemistry with SERPINA3 antibodies has been used on tissue microarrays to demonstrate significantly increased SERPINA3 expression in invasive and metastatic melanomas compared to normal nevi and melanoma-in-situ . The protocol typically involves tissue fixation with 4% formaldehyde, antigen retrieval using citric acid buffer (pH 6.0), blocking with normal goat serum, and overnight incubation with SERPINA3 antibody (dilution 1:200) .

To investigate functional roles in cancer cell lines, researchers have used siRNA-mediated downregulation of SERPINA3 expression followed by invasion assays using Transwell plates with Matrigel coating . These experiments revealed that the ability of melanoma cells to invade through Matrigel was severely impaired with downregulation of SERPINA3 expression, suggesting a critical role in the invasive capacity of cancer cells .

Additionally, Western blotting and qPCR can be employed to correlate SERPINA3 expression with EMT markers and drug resistance proteins, providing mechanistic insights into how SERPINA3 contributes to cancer progression and treatment resistance .

What are the considerations for using SERPINA3 antibodies in co-localization studies?

Co-localization studies with SERPINA3 antibodies require careful planning to generate reliable and meaningful results. From the search results, we can see that fluorescence co-localization staining has been used to study the localization of chymase and SERPINA3 , which provides insights into their functional relationship.

When designing co-localization experiments with SERPINA3 antibodies, consider the following:

• Antibody compatibility: Ensure that primary antibodies originate from different host species to prevent cross-reactivity. In the example from the search results, they used anti-SERPINA3 antibody (ab205198, Abcam, 1:2000) and anti-mast cell chymase antibody (ab186417, Abcam, 1:250) .

• Fluorophore selection: Choose fluorophores with minimal spectral overlap to avoid bleed-through artifacts. Secondary antibodies should be selected with complementary fluorophores that match your imaging system's filter sets.

• Controls: Include single-stained controls and secondary-only controls to account for autofluorescence and non-specific binding.

• Image acquisition: Use a confocal microscope (as mentioned in the search results: LeicaSP5-FCS, Wetzlar, Germany) for improved spatial resolution of co-localization .

• Quantitative analysis: Employ appropriate software for quantitative co-localization analysis. The search results mention using ImageJ software with the plugin Coloc 2 for correlation analysis .

When interpreting co-localization data, consider that spatial proximity doesn't necessarily prove functional interaction. Complementary techniques such as proximity ligation assays or co-immunoprecipitation may provide additional evidence for protein-protein interactions involving SERPINA3.

How can SERPINA3 antibodies be used to study its role in disease mechanisms beyond cancer?

While much research has focused on SERPINA3's role in cancer, this protein has been implicated in various other diseases, including Alzheimer's disease, liver disease, and diabetic nephropathy . SERPINA3 antibodies can be valuable tools in studying these disease mechanisms:

For Alzheimer's disease research, SERPINA3 antibodies can be used in immunohistochemistry of brain tissue to examine the spatial relationship between SERPINA3 and amyloid plaques or neurofibrillary tangles. Given that variations in SERPINA3's sequence have been implicated in Alzheimer's disease , antibodies specific to different variants may help elucidate their differential roles in pathogenesis.

In diabetic nephropathy research, SERPINA3 levels in urine and blood samples have been measured using ELISA kits . The search results describe a protocol where "blood serum and urine samples were obtained from healthy volunteers and patients and diluted 5,000 and 100 times, respectively" . This approach allows for quantitative assessment of SERPINA3 as a potential biomarker for disease progression or treatment response.

Immunohistochemistry has also been used to investigate SERPINA3 expression differences between patients with diabetic nephropathy and healthy individuals, using anti-SERPINA3 antibody (ab205198, Abcam, 1:2000) . This technique can help identify the specific cell types and tissue regions where SERPINA3 may be contributing to disease pathology.

What are the optimal conditions for using SERPINA3 antibodies in immunohistochemistry?

Based on the search results, several protocols have been described for using SERPINA3 antibodies in immunohistochemistry with varying conditions depending on the specific tissue and detection method:

For formalin-fixed paraffin-embedded (FFPE) tissues, a standard protocol involves:

• Tissue fixation with 4% formaldehyde buffer

• Sectioning into 4-μm-thick slices

• Incubation at 60°C for 2 hours before dewaxing

• Antigen retrieval by autoclaving at 115°C for 3 minutes in citric acid buffer (pH 6.0)

• Quenching endogenous peroxidase activity with 0.3% H₂O₂ solution for 15 minutes

• Blocking with normal goat serum for 45 minutes

• Overnight incubation with primary SERPINA3 antibody (dilution 1:200) at 4°C

• Treatment with appropriate secondary antibody for 30 minutes at room temperature

• Visualization using 3,3′-diaminobenzidine (DAB)

• Image capture using appropriate microscopy

For fluorescence-based detection, the protocol may be adjusted with:

• Similar tissue preparation steps

• Specific anti-SERPINA3 antibody (e.g., ab205198, Abcam) at 1:2000 dilution

• Fluorophore-conjugated secondary antibodies

• Confocal microscopy for image collection (e.g., LeicaSP5-FCS)

Optimization factors to consider include:

• Antibody dilution (ranges from 1:200 to 1:2000 in the search results)

• Antigen retrieval method (citric acid buffer is commonly used)

• Incubation time and temperature for primary antibody

• Detection system (chromogenic vs. fluorescent)

Each parameter may need to be optimized for specific tissue types and research questions.

What are the best practices for using SERPINA3 antibodies in ELISA?

ELISA is a common application for SERPINA3 antibodies, particularly for quantifying SERPINA3 levels in biological samples. Based on the search results, here are best practices:

For sandwich ELISA:

• Use validated antibody pairs, such as the matched antibody pair mentioned in search result : 66078-2-PBS for capture and 66078-3-PBS for detection, which has been validated for cytometric bead array .

• The commercially available SERPINA3 ELISA kit described in search result uses an antibody specific for SERPINA3 pre-coated onto microwells. The SERPINA3 protein in samples is captured by this coated antibody after incubation, followed by addition of another SERPINA3-specific antibody for detection .

• For signal development, an HRP-conjugated antibody is added, followed by TMB reagent. The reaction is stopped with sulfuric acid, and absorbance is measured at 450nm with correction at 630nm .

Sample considerations:

• Sample types validated for SERPINA3 ELISA include serum and plasma .

• Proper sample dilution is critical: according to search result , blood serum samples may require dilution of 5,000 times while urine samples may be diluted 100 times .

• Recovery rates for human plasma samples range from 82% to 113%, with an average of 99% .

Performance characteristics:

• The sensitivity of the ELISA kit described is 0.55 ng/mL .

• The detection range is 1-64 ng/mL .

For optimal results, consider:

• Including a standard curve on each plate

• Running all samples in duplicate or triplicate

• Including quality control samples

• Ensuring consistent incubation times and temperatures

• Thorough washing between steps to reduce background

How can I troubleshoot non-specific binding issues with SERPINA3 antibodies?

Non-specific binding is a common challenge when working with antibodies, including those targeting SERPINA3. Based on general antibody principles and information from the search results, here are troubleshooting approaches:

• Antibody validation: Ensure you're using a well-validated antibody for your specific application. The search results mention several validated antibodies for different applications . Some antibodies may perform well in one application (e.g., ELISA) but show non-specific binding in others (e.g., Western blot).

• Optimize blocking conditions: Non-specific binding often results from inadequate blocking. In the immunohistochemistry protocol mentioned, normal goat serum was used for 45 minutes to block non-specific binding . Consider testing different blocking agents (BSA, casein, commercial blocking buffers) and extending blocking time.

• Antibody dilution optimization: Test a range of antibody dilutions. The search results show a wide range of recommended dilutions for different applications, from 1:10 to 1:2000 . Too high a concentration can increase non-specific binding.

• Secondary antibody considerations: Ensure your secondary antibody is appropriate for your primary antibody host species and isotype. For example, if using the mouse monoclonal SERPINA3 antibody of IgG1 isotype , select a secondary antibody specifically targeting mouse IgG1.

• Additional controls: Include isotype controls matching your primary antibody to identify non-specific binding due to Fc receptor interactions. Also include secondary-only controls to detect non-specific binding of the secondary antibody.

• Sample preparation: Ensure proper sample preparation. For tissue sections, ensure adequate fixation and antigen retrieval as described in the immunohistochemistry protocol .

• Washing optimization: Increase washing duration or number of washes to remove unbound antibody. Use appropriate detergent concentrations in wash buffers.

• Cross-adsorbed secondary antibodies: For multiple labeling experiments, use cross-adsorbed secondary antibodies to minimize cross-reactivity between detection systems.

How should I select the appropriate SERPINA3 antibody for my specific research question?

Selecting the right SERPINA3 antibody requires careful consideration of multiple factors to ensure it will perform optimally for your specific research application:

• Research application: Different antibodies are validated for different applications. From the search results, we can see antibodies validated for various techniques:

  • For Western blotting: Polyclonal antibodies often work well as they recognize multiple epitopes, potentially providing stronger signals with denatured proteins .

  • For immunohistochemistry: Both monoclonal and polyclonal options are available with specific validated protocols .

  • For ELISA: Consider matched antibody pairs specifically validated for this purpose, such as 66078-2-PBS (capture) and 66078-3-PBS (detection) .

• Species reactivity: Ensure the antibody recognizes SERPINA3 from your species of interest. The search results primarily mention human-reactive antibodies , though some antibodies with mouse reactivity are also mentioned .

• Epitope location: Consider whether the specific region of SERPINA3 recognized by the antibody is relevant to your research. Some antibodies target specific regions, such as:

  • N-terminal region (AA 23-253)

  • C-terminal region (AA 279-432)

  • Full-length protein (AA 1-423)

  • KLH-conjugated synthetic peptide between 282-310 amino acids from the C-terminal region

• Antibody format: Depending on your application, you may need:

  • Unconjugated antibodies for flexibility in detection methods

  • Conjugation-ready formulations for custom labeling approaches

  • Pre-conjugated antibodies for direct detection

• Validation data: Review the manufacturer's validation data for your specific application. Look for:

  • Images showing expected staining patterns

  • Positive and negative controls

  • Quantitative data demonstrating specificity and sensitivity

  • Technical replicates showing reproducibility

• Buffer compatibility: Consider whether the antibody's storage buffer is compatible with your experimental system. Some antibodies are provided in PBS only (BSA and azide free), making them ready for conjugation , while others contain sodium azide , which may interfere with certain applications.

What are the key considerations when measuring SERPINA3 levels in patient samples?

Measuring SERPINA3 levels in patient samples for research or clinical studies requires attention to several important factors:

• Sample type selection: SERPINA3 can be measured in multiple sample types:

  • Serum and plasma have been validated for SERPINA3 ELISA

  • Urine has also been used for SERPINA3 detection in diabetic nephropathy research

  • Tissue samples can be analyzed using immunohistochemistry

  The choice depends on your research question and the biological compartment most relevant to the disease process.

• Sample handling and processing:

  • For blood: Collection method, anticoagulant choice, and processing time can affect protein stability

  • For urine: Specify whether spot samples or 24-hour collections are used

  • For tissues: Fixation method and time impact epitope preservation and antibody binding

• Sample dilution optimization: Different sample types require different dilution factors:

  • Blood serum samples may require significant dilution (5,000x reported in one protocol)

  • Urine samples typically require less dilution (100x)

  • Optimal dilution should be determined empirically to ensure measurements fall within the assay's dynamic range (1-64 ng/mL for the ELISA kit described)

• Reference ranges and controls:

  • Include age- and sex-matched healthy controls

  • Consider disease controls (other related conditions) to assess specificity

  • Establish reference ranges appropriate for your patient population

• Pre-analytical variables:

  • Document patient characteristics (age, sex, comorbidities)

  • Record relevant medications that might affect SERPINA3 levels

  • Consider diurnal variation and standardize collection timing

• Assay selection and validation:

  • ELISA kits such as the one described in search result offer standardized measurement

  • Sensitivity (0.55 ng/mL) and range (1-64 ng/mL) should be appropriate for expected concentrations

  • Recovery rates (82%-113% for human plasma) should be considered when interpreting results

• Data normalization: Consider whether measurements should be normalized to total protein, creatinine (for urine), or other parameters depending on the sample type and research question.

How can I use SERPINA3 antibodies to investigate protein-protein interactions?

Investigating SERPINA3's interactions with other proteins is crucial for understanding its biological functions and role in disease mechanisms. The search results provide insights into techniques using SERPINA3 antibodies for this purpose:

• Co-localization studies: Fluorescence co-localization staining has been used to study the localization relationship between chymase and SERPINA3 . This approach involves:

  • Using primary antibodies from different host species (e.g., anti-SERPINA3 antibody ab205198 and anti-mast cell chymase antibody ab186417)

  • Detecting with species-specific secondary antibodies conjugated to different fluorophores

  • Imaging with confocal microscopy

  • Analyzing co-localization using software such as ImageJ with the Coloc 2 plugin

  While co-localization suggests spatial proximity, it doesn't definitively prove direct interaction.

• Co-immunoprecipitation (Co-IP): Though not explicitly mentioned in the search results, Co-IP is a standard technique for studying protein-protein interactions:

  • Use SERPINA3 antibodies to immunoprecipitate SERPINA3 from cell or tissue lysates

  • Analyze co-precipitated proteins by Western blotting with antibodies against suspected interaction partners

  • Include appropriate controls (isotype control, beads-only)

• Proximity Ligation Assay (PLA): This technique provides higher specificity than standard co-localization:

  • Primary antibodies against SERPINA3 and its potential interaction partner bind to their targets

  • Secondary antibodies with attached oligonucleotides bring the oligonucleotides into close proximity if the proteins interact

  • Rolling circle amplification creates a fluorescent signal only when proteins are within ~40 nm

  • This technique offers higher specificity than standard co-localization

• Functional validation of interactions: After identifying potential interactions, functional validation might include:

  • siRNA-mediated knockdown of SERPINA3 to observe effects on the interaction partner's function or localization

  • Mutation of key residues in SERPINA3 to disrupt specific interactions

  • Competitive binding assays using purified proteins

• Correlation of expression levels: In tissues or cell populations, correlation between SERPINA3 and potential interaction partners can provide supportive evidence:

  • Immunohistochemistry on serial sections to compare expression patterns

  • Dual immunofluorescence to quantify correlation of expression levels

  • Western blotting of fractionated samples to determine subcellular co-distribution

How can SERPINA3 antibodies be used in multiplex protein detection systems?

Multiplex detection systems allow simultaneous measurement of multiple proteins, providing more comprehensive analysis while conserving precious samples. The search results indicate that SERPINA3 antibodies have been validated for multiplex approaches:

Search result specifically mentions that a matched antibody pair (66078-2-PBS for capture and 66078-3-PBS for detection) has been validated for cytometric bead array, which is a common multiplex platform . This technology uses beads of different fluorescent intensities, each coated with antibodies against different targets, allowing simultaneous detection of multiple proteins in a single sample.

For implementing SERPINA3 in multiplex detection systems:

• Bead-based multiplex assays:

  • Ensure antibody pairs are validated specifically for multiplex platforms to minimize cross-reactivity

  • The unconjugated mouse monoclonal antibody described in result is provided in PBS only (BSA and azide free), making it "ready for conjugation" and ideal for "multiplex assays requiring matched pairs"

  • Optimize antibody concentrations to ensure balanced signal across all analytes

  • Include proper controls to assess cross-reactivity between detection systems

• Multiplex immunofluorescence imaging:

  • Select primary antibodies from different host species to avoid cross-reactivity

  • Use secondary antibodies with minimal spectral overlap

  • Consider sequential staining protocols for complex panels

  • Employ appropriate unmixing algorithms during image analysis

  • Antibody 66078-3-PBS is specifically noted as suitable for "multiplex imaging applications"

• Mass cytometry:

  • SERPINA3 antibodies can be conjugated to rare earth metals for mass cytometry (CyTOF)

  • The conjugation-ready format mentioned in result would be suitable for metal labeling

  • This approach allows for highly multiplexed protein detection at the single-cell level

• Digital spatial profiling:

  • SERPINA3 antibodies can be incorporated into panels for spatial analysis of protein expression in tissue sections

  • This technique provides both spatial context and quantitative measurement

Each of these multiplex approaches requires careful validation to ensure specificity and sensitivity when SERPINA3 detection is combined with other targets.

What are the emerging applications of SERPINA3 antibodies in biomarker research?

SERPINA3 is emerging as a potential biomarker across multiple disease contexts, with antibody-based detection playing a crucial role in its validation and implementation:

• Cancer biomarker applications:

  • SERPINA3 overexpression correlates with high mortality in melanoma patients, suggesting its potential as a prognostic biomarker

  • In breast cancer, particularly triple-negative breast cancer (TNBC), SERPINA3 promotes tumor invasion and confers cisplatin resistance, indicating potential as both a prognostic and predictive biomarker

  • Immunohistochemistry using SERPINA3 antibodies on tissue microarrays has demonstrated significant increases in SERPINA3 expression in invasive and metastatic melanomas compared to normal nevi and melanoma-in-situ

• Diabetic nephropathy biomarker development:

  • SERPINA3 has been investigated as an "immune-related" biomarker involved in diabetic nephropathy

  • ELISA-based detection of SERPINA3 in urine and blood samples has been employed to assess its utility in patient stratification or disease monitoring

  • The different dilution requirements for blood (5,000x) versus urine (100x) suggest tissue-specific regulation of SERPINA3 levels

• Neurodegenerative disease applications:

  • Variations in SERPINA3 sequence have been implicated in Alzheimer's disease

  • Antibodies specific to different SERPINA3 variants could help identify patients with particular risk profiles

• Liquid biopsy development:

  • ELISA kits with sensitivity of 0.55 ng/mL and range of 1-64 ng/mL enable reliable quantification of SERPINA3 in serum and plasma samples

  • Recovery rates for human plasma (average 99%, range 82%-113%) indicate reliable measurement in this sample type

  • These performance characteristics support SERPINA3's potential integration into multi-marker liquid biopsy panels

Emerging methodologies for biomarker implementation include:

• Automated immunohistochemistry platforms for standardized tissue analysis

• Point-of-care ELISA or lateral flow assays for rapid assessment

• Integration into multiparameter predictive models combining multiple biomarkers

• Longitudinal monitoring approaches to assess treatment response

What are the considerations for developing new SERPINA3 antibodies for specialized research applications?

Researchers developing new SERPINA3 antibodies for specialized applications should consider several critical factors to ensure optimal performance:

• Epitope selection:

  • The search results show antibodies targeting various regions of SERPINA3, including:

    • Full-length protein (AA 1-423)

    • N-terminal region (AA 23-253)

    • C-terminal region (AA 279-432)

    • KLH-conjugated synthetic peptide between 282-310 amino acids

  • For functional blocking antibodies, target known functional domains or protein-protein interaction sites

  • For detection of specific variants or isoforms, select epitopes that differ between variants

  • Consider epitope accessibility in native versus denatured proteins depending on intended applications

• Immunogen design:

  • Recombinant proteins: One antibody was generated using "SERPINA3,AACT fusion protein Ag2830"

  • Synthetic peptides: Another used "KLH-conjugated synthetic peptide between 282-310 amino acids from the C-terminal region"

  • For phospho-specific antibodies, design peptides containing the phosphorylated residue of interest

  • Consider carrier protein selection to enhance immunogenicity while minimizing irrelevant immune responses

• Host species selection:

  • The search results show both mouse and rabbit hosts for SERPINA3 antibodies

  • Choose host species compatible with intended experimental systems

  • Consider species evolutionary distance from target protein for optimal immunogenicity

  • For multiplex applications, select different host species for different targets

• Purification and validation strategies:

  • Protein G affinity purification has been used for mouse monoclonal antibodies

  • Validation should include:

    • Specificity testing (Western blot, knockdown controls)

    • Cross-reactivity assessment against related serpins

    • Application-specific validation (e.g., immunoprecipitation efficiency)

    • Lot-to-lot consistency testing

• Specialized modifications:

  • For ELISA matched pairs, develop and validate both capture and detection antibodies recognizing different epitopes

  • For multiplex imaging, ensure compatibility with tissue fixation and antigen retrieval methods

  • For flow cytometry, optimize antibody performance in cell suspension formats

  • Consider conjugation-ready formats (PBS only, BSA and azide free) for flexibility in downstream applications

• Patent and intellectual property considerations:

  • Review existing patents on SERPINA3 antibodies and epitopes

  • Consider freedom-to-operate analysis for commercial development

  • Document development process for potential intellectual property protection